DNL
vs
F
FTSE All Share Index
DNL
Over the past 12 months, DNL has underperformed FTSE All Share Index, delivering a return of 0% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
DNL vs FTSE All Share Index
Performance Gap
DNL vs FTSE All Share Index
Performance By Year
DNL vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Diurnal Group PLC
Glance View
Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. The firm is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism. Its research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The firm's product, Alkindi, is a hydrocortisone specifically designed for use in children suffering from pediatric adrenal insufficiency (AI). Alkindi is an oral, immediate-release pediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children. Its pipeline includes Chronocort, DITEST, T3 modified release and Oligonucleotide (siRNA). Chronocort is a modified-release preparation of hydrocortisone that is specifically designed to mimic the circadian rhythm of cortisol.
